Lacosamide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Lacosamide

Examples of brand names: Vimpat [EU/DE]

ATC code: N03AX18

Main use (for orientation): Epilepsy

Documented research summary

Gaston 2023, n=45: no statistical lacosamide concentration signal with CBD (p=0.4971), not evidence of equivalence. Mouse data show tissue-concentration effects without altered seizure protection; not transferable to clinical exposure. Rare cannabinoids unresolved.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0064

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.4971.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=45.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

CBD – laboratory and animal studies

Finding ID: B0349

Type of result: Preclinical evidence

Observation: CBD increased lacosamide brain concentrations; lacosamide increased CBD brain concentrations. No change in lacosamide seizure inhibition in the 6 Hz model.

Mechanism: Preclinical pharmacokinetics with unchanged measured seizure effect

Study type: Mouse experiment

Context studied: Socała 2019, abstract; serum/brain HPLC, separate medicine combinations.

Clinical interpretation: Do not infer a human drug–drug interaction or dosage.

Limitations and uncertainties: Full text inaccessible; do not add exposure figures not provided in the abstract.

Original sources for this finding: Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. [CA_P_31377197]

References and access status

[C_LABEL_D0050] LACOSAMIDE (LACOSAMIDE) TABLET, FILM COATED [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_31377197] Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.

Original source / bibliographic reference

Authors: Socała K, Wyska E, Szafarz M, Nieoczym D, Wlaź P.

Year: 2019

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1016/j.neuropharm.2019.107733

PMID: 31377197

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_33981514] Refractory Seizure in a Patient With Griscelli Syndrome: A Unique Case With One Mutation and a Novel Deletion.

Original source / bibliographic reference

Authors: Ortiz JF, Ruxmohan S, Alzamora IM, Patel A, Eissa-Garcés A.

Year: 2021

Source type: Primary source, abstract read

DOI: 10.7759/cureus.14402

PMID: 33981514

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility